Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients

被引：29

作者：

Benard, Antoine ^{[1
]}

Damond, Florence ^{[2
]}

Campa, Pauline ^{[3
]}

Peytavin, Gilles ^{[4
]}

Descamps, Diane ^{[2
]}

Lascoux-Combes, Caroline ^{[6
]}

Taieb, Audrey

Simon, Francois ^{[5
]}

Autran, Brigitte ^{[7
]}

Brun-Vezinet, Francoise ^{[2
]}

Chene, Genevieve

Matheron, Sophie ^{[8
]}

机构：

[1] Univ Victor Segalen Bordeaux 2, INSERM, U897,ANRS, CMG EC,CIC EC 7,ISPED, F-33076 Bordeaux, France

[2] CHU Bichat Claude Bernard, Virol Lab, APHP, Paris, France

[3] CHU St Antoine, Serv Malad Infect & Trop, APHP, Paris, France

[4] CHU Bichat Claude Bernard, Serv Pharmacol, APHP, Paris, France

[5] CHU St Louis, Virol Lab, APHP, Paris, France

[6] Serv Med Interne, APHP, Paris, France

[7] CHU Pitie Salpetriere, Lab Immunol Cellulaire, APHP, Paris, France

[8] Univ Paris 07, CHU Bichat Claude Bernard, Serv Malad Infect & Trop, APHP, Paris, France

来源：

AIDS | 2009年 / 23卷 / 09期

关键词：

PLASMA VIRAL LOAD; HIV-2; INFECTION; SUSCEPTIBILITY; THERAPY; CALL;

D O I：

10.1097/QAD.0b013e32832949f0

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In 29 antiretroviral-naive HIV-2-infected patients starting lopinavir/ritonavir-containing regimen, the median CD4 cell count change from baseline (142 cells/mu l) was +71 cells/mu l at week 24 and +132 cells/mu l at week 96. Seventeen (59%) patients had a CD4 cell count increase of at least 50 cells/mu l and undetectable HIV-2 RNA at week 24 and were considered as responders to treatment. This sustained elevation of CD4 cell count in the first 2 years of combination antiretroviral therapy shows the potential for lopinavir/ritonavir regimens as first-line therapy in HIV-2 infection.

引用

页码：1171 / 1173

页数：3

共 15 条

[1] Antiretroviral therapy in HIV-2-infected patients:: changes in plasma viral load, CD4+cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire [J].

Adjé-Touré, CA ;

Cheingsong, R ;

Garcìa-Lerma, JG ;

Eholié, S ;

Borget, MY ;

Bouchez, JM ;

Otten, RA ;

Maurice, C ;

Sassan-Morokro, M ;

Ekpini, RE ;

Nolan, M ;

Chorba, T ;

Heneine, W ;

Nkengasong, JN .

AIDS, 2003, 17 :S49-S54

[2] Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay [J].

Damond, F ;

Collin, G ;

Descamps, D ;

Matheron, S ;

Pueyo, S ;

Taieb, A ;

Campa, P ;

Benard, A ;

Chêne, G ;

Brun-Vezinet, F .

JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (08) :4234-4236

[3] Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors [J].

Damond, F ;

Brun-Vezinet, F ;

Matheron, S ;

Peytavin, G ;

Campa, P ;

Pueyo, S ;

Mammano, F ;

Lastere, S ;

Farfara, I ;

Simon, F ;

Chene, G ;

Descamps, D .

JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (01) :484-487

[4] Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections [J].

Damond, F ;

Gueudin, M ;

Pueyo, S ;

Farfara, I ;

Robertson, DL ;

Descamps, D ;

Chène, G ;

Matheron, S ;

Campa, P ;

Brun-Vézinet, F ;

Simon, F .

JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (10) :3654-3659

[5] Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients [J].

Delfraissy, Jean-Fran Ois ;

Flandre, Philippe ;

Delaugerre, Constance ;

Ghosn, Jade ;

Horban, Andrzej ;

Girard, Pierre-Marie ;

Norton, Michael ;

Rouzioux, Christine ;

Taburet, Anne-Marie ;

Cohen-Codar, Isabelle ;

Van, Philippe Ngo ;

Chauvin, Jean-Pierre .

AIDS, 2008, 22 (03) :385-393

[6] In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors [J].

Desbois, Delphine ;

Roquebert, Benedicte ;

Peytavin, Gilles ;

Damond, Florence ;

Collin, Gilles ;

Bernard, Antoine ;

Campa, Pauline ;

Matheron, Sophie ;

Chene, Genevieve ;

Brun-Vezinet, Francoise ;

Descamps, Diane .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (04) :1545-1548

[7] Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France [J].

Drylewicz, Julia ;

Matheron, Sophie ;

Lazaro, Estibaliz ;

Damond, Florence ;

Bonnet, Fabrice ;

Simon, Francois ;

Dabis, Francois ;

Brun-Vezinet, Francoise ;

Chene, Genevieve ;

Thiebaut, Rodolphe .

AIDS, 2008, 22 (04) :457-468

[8] The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacovir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial (vol 368, pg 476, 2006) [J].

Eron, Joseph, Jr. ;

Yeni, Patrick ;

Gathe, Joseph .

LANCET, 2006, 368 (9543) :1238-1238

[9] A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa [J].

Gottlieb, Geoffrey S. ;

Eholie, Serge-Paul ;

Nkengasong, John N. ;

Jallow, Sabelle ;

Rowland-Jones, Sarah ;

Whittle, Hilton C. ;

Sow, Papa Salif .

AIDS, 2008, 22 (16) :2069-2072

[10] CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5HIV-2 cohort [J].

Matheron, S ;

Damond, F ;

Benard, A ;

Taieb, A ;

Campa, P ;

Peytavin, G ;

Pueyo, S ;

Brun-Vezinet, F ;

Chene, G .

AIDS, 2006, 20 (03) :459-462

← 1 2 →